John R Fischer

PE seeks assets in oncology: 6 deals

AEA Investors, Bridgepoint and Kohlberg are among the PE firms investing in assets in the oncology sector.

What Kinderhook hopes to gain from $1.1bn take-private of Enhabit

'The fragmented industry has started to get consolidated amongst the larger players, and Enhabit is the largest independent remaining,' says Kinderhook Industries' Matt Bubis.

Charterhouse, Iron Path, Revelar Capital seek pain management assets; Orthopedic care spurs merger between Charlesbank and Nordic manufacturers

Exploring private equity interest in the pain management sector; a look at the completed merger of two medtech manufacturers into an orthopedics-focused platform and backed by Charlesbank Capital Partners and Nordic Capital.

PE targets pain management: 5 deals

Charterhouse Capital, Iron Path and Revelar Capital are among the PE firms investing in platforms and add-ons for pain management.

Blackstone, Audax, Five Arrows eye pharmaceutical and life science consulting firms; Drug R&D complexity drives Eir Partners to invest in QuartzBio

Discussing the platform and M&A opportunities firms see in the pharmaceutical and life science sector; a look at Eir Partners’ investment in a life sciences data analytics company; insights from a conference hosted by Houlihan Lokey on what’s needed to leverage AI to help businesses thrive in the era of disintermediation.

PE seeks pharmaceutical and life sciences consulting firms: 7 deals

Blackstone, Audax, Bridgepoint and Baird are among the PE firms targeting add-ons for pharmaceutical and life science consultancy platforms.

PE zeros in on telehealth demand: 5 deals

Goldman Sachs, Avesi Partners, Grovecourt Capital and QC Capital are among the PE firms investing in telehealth companies.

Goldman Sachs, GHO, MidEuropa set sights on eye care; Medical component demand drives Artemis’ acquisition of Optikos

With sizable and stable EBITDA multiples, ophthalmology assets have become highly sought after by private equity.

PE targets eye care assets: 6 deals

Goldman Sachs, Gryphon Investors, MidEuropa and Olympus are among the PE firms eying platform investments and consolidation in eye care.

Astorg eyes ‘wealth of opportunities’ for Thermo Fisher microbiology biz; Mid-market firms poised to back pharmacies

Discussing Astorg's plans for scaling Thermo Fisher’s microbiology business, which it agreed to buy for over $1 billion; lots of opportunities in pharmacies in the middle market, as folks from law firm Bass, Berry & Sims explain.